OncoMatch/Clinical Trials/NCT06582446
Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)
Is NCT06582446 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Androgen Deprivation Therapy (ADT) - Goserelin for prostate cancer.
Treatment: Androgen Deprivation Therapy (ADT) - Goserelin — A prospective, single-arm phase II study is the individualization of RT for patients with high-risk localized PCa based on multimodal artificial intelligence (MMAI). All patients will receive the current standard of care: (i) a dose escalation to the prostate via HDR brachytherapy, (ii) two years of ADT and (iii) whole-pelvis UHF-RT (5 fractions).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage HIGH-RISK, VERY HIGH-RISK (NCCNv1.2023)
Excluded: Stage CN+, CM+
High- or very high-risk according to NCCNv1.2023 criteria; Evidence of pelvic nodal disease (cN+) in mpMRI and/or PSMA-PET/CT [excluded]; Evidence of distant metastatic disease (cM+) in mpMRI and/or PSMA-PET/CT [excluded]; Evidence of cT4 disease in mpMRI and/or PSMA-PET/CT [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiotherapy
Prior radiotherapy to the prostate or pelvis
Cannot have received: radical prostatectomy
Prior radical prostatectomy
Cannot have received: focal therapy
Prior focal therapy approaches to the prostate
Cannot have received: prostate surgery (TURP, HOLEP)
Exception: significant tissue cavity or within the last 6 months prior to randomization
Prostate surgery (TURP or HOLEP) with a significant tissue cavity or prostate surgery (TURP or HOLEP) within the last 6 months prior to randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06582446 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy, radical prostatectomy, focal therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage HIGH-RISK or VERY HIGH-RISK is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages